洛塞那肽和利拉鲁肽辅助治疗对糖尿病肾病的效果及对氧化应激指标和Hcy、Cys-C、β2-MG水平的影响  

Clinical Efficacy of Polyethylene Glycol Loxenatide and Liraglutide Adjuvant Therapy in Diabetic Nephropathy and the Effect on Oxidative Stress Indicators and Hcy,Cys-C andβ2-MG Levels

作　　者：刘星星 杨寒 Liu Xingxing;Yang Han(Nanshi Hospital Affiliated to Henan University,Nanyang 473006)

机构地区：[1]河南大学附属南石医院,河南南阳473006

出　　处：《辽宁医学杂志》2025年第1期32-35,共4页Medical Journal of Liaoning

摘　　要：目的探究洛塞纳肽和利拉鲁肽辅助治疗对糖尿病肾病的效果及对氧化应激指标和血清同型半胱氨酸(Hcy)、血清胱抑素(Cys-C)、尿β2-微球蛋白(β2-MG)水平的影响。方法选取2021年4月至2023年1月于许昌市人民医院内分泌科收治的300例糖尿病肾病患者,采用抽签法将其随机分为洛塞纳肽组(n=150)和利拉鲁肽组(n=150)。洛塞纳肽组采用洛塞纳肽与二甲双胍治疗,利拉鲁肽采用利拉鲁肽与二甲双胍治疗。两组均治疗2个月,比较两组的治疗总有效率、糖代谢指标[空腹血糖(FPG)、糖化血红蛋白(HbA1c)以及餐后2小时血糖(2 h PG)]和肾功能水平[肾小球滤过率(GFR)、尿酸(UA)和尿白蛋白肌酐比值(UACR)]、氧化应激指标[总抗氧化能力(T-AOC)、丙二醛(MDA)和谷胱甘肽过氧化氢物酶(GSH-Px)]和Hcy、Cys-C、β2-MG水平。结果洛塞纳肽组与利拉鲁肽组的治疗总有效率、糖代谢指标(FPG、HbA1c、2 h PG)和肾功能水平(GFR、UA和UACR)治疗前后均无明显差异(P>0.05)。两组患者的氧化应激指标(T-AOC、MDA、GSH-Px)及Hcy、Cys-C、β2-MG水平无明显差异(P>0.05)。结论洛塞纳肽和利拉鲁肽辅助治疗对于糖尿病肾病的疗效相当,使用两种药物后对氧化应激指标和Hcy、Cys-C、β2-MG水平影响无明显差别。Objective To explore the clinical efficacy of polyethylene glycol loxenatide and liraglutide adjuvant therapy in diabetic nephropathy and the effect on oxidative stress indicators and homocysteine(Hcy),cystatin C(Cys-C)andβ2-microglobulin(β2-MG)levels.Methods Three hundred patients with diabetic nephropathy admitted to the Endocrinology Department of Xuchang People′s Hospital from April 2021 to January 2023 were selected,and randomly assigned into two groups,each with 150 cases.Loxenatide group received loxenatide and metformin,while liraglutide group was given liraglutide plus metformin.Treatment in both groups lasted for 2 months.Then the overall efficacy rate,glucose metabolism index[fasting plasma glucose(FPG),glycosylated hemoglobin(HbA1c),2 h postprandial plasma glucose(2 h PG)],renal function parameters[glomerular filtration rate(GFR),urinary albumin(UA),urinary albumin-to-creatinine ratio(UACR)],oxidative stress markers[total antioxidant capacity(T-AOC),malondialdehyde(MDA)and glutathione peroxidase(GSH-Px)],Hcy,Cys-C,andβ2-MG levels were compared between groups.Results The overall efficacy,as well as the pre-and post-treatment glucose metabolism indicators(FPG,HbA1c,2 h PG)and renal function parameters(GFR,UA and UACR)yielded no statistical difference between two groups(all P>0.05).No statistical difference was found in the oxidative stress indicators(T-AOC,MDA,GSH-Px),Hcy,Cys-C andβ2-MG between two groups(all P>0.05).Conclusion The efficacy of polyethylene glycol loxenatide and liraglutide adjuvant therapy in diabetic nephropathy is comparable,and the impact of two treatment regimens on oxidative stress indicators and Hcy,Cys-C andβ2-MG levels is also similar.

关 键 词：洛塞纳肽 利拉鲁肽 糖尿病肾病 氧化应激 

分 类 号：R58[医药卫生—内分泌]